Eribulin versus Treatment of Physician’s Choice for Patients with Heavily Pretreated Advanced Breast Cancer
Eribulin versus Treatment of Physician's Choice for Patients with Heavily Pretreated Advanced Breast Cancer
Slides from a presentation at ASCO 2010 and transcribed comments from recent interviews with Adam M Brufsky, MD, PhD (6/18/10) and Linda T Vahdat, MD (6/5/10)
Twelves C et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician’s choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. Proc ASCO 2010;Abstract CRA1004. |
||||||||